Phase 3 was completed. They extended it to do an open label extension study I believe. https://emalexbiosciences.com/news/emalex-biosciences-lead-candidate-meets-primary-and-secondary-endpoints-in-phase-3-tourette-syndrome-study/ According to everything I am reading, once fda approval is received, it usually is available within weeks for the UsA.